BioCorp and Diabeloop announced today that they are entering a cooperation agreement to develop new personalized diabetes treatments.
Diabeloop develops automated insulin delivery (AID) systems, including a self-learning algorithm hosted in a handset and connected to a continuous glucose monitoring (CGM) system and an insulin pump. The platform analyzes glucose data, calculates the right dose of insulin for administration and automatically administers it.
BioCorp develops Mallya, an intelligent sensor for insulin injection pens that has CE mark approval in Europe. The platform is compatible with any disposable insulin pen and enables reliable monitoring for doses selected for injection and it offers patients with diabetes better compliance with their treatment.